Tate & Lyle PLC

TATE: XLON (GBR)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|^tLOCK|<K$Z#LOCK|%FKR<L>

Tate & Lyle Earnings: Sales Return to Volume-Led Growth; Ingredion Deal Is on Track

Tate & Lyle's sales recovered to 1% growth for fiscal first half, from a 3% decline in the first quarter. Growth was volume-driven (+3%), offsetting negative price. The proposed acquisition by Ingredion is on track to close in the second half of calendar year 2027, subject to regulatory approvals.

Sponsor Center